Company (Location)

Product

Description

Indication

Status (Date)#

Bristol-Myers Squibb Co. (New York)

BMS-790052

An NS5A replication complex inhibitor

Hepatitis C virus

Phase II data of BMS-790052 in combination with peginterferon alfa and ribavirin showed that 83% (60 mg), 83% (10 mg) and 42% (3 mg) of patients maintained undetectable viral loads at 24 weeks post-treatment, compared to 25% of patients in the peginterferon/ribavirin group (9/20)

Dynavax Technologies Corp. (Berkeley, Calif.)

Heplisav

Vaccine

Hepatitis B virus

Phase III results demonstrated its ability to generate a faster, higher and longer-lasting response compared to Engerix-B (9/20)

Merck & Co. Inc. (Whitehouse Station, N.J.)

Isentress

Integrase inhibitor; raltegravir

HIV

Study results showed that after 48 weeks of treatment, Isentress in combination therapy demonstrated efficacy and tolerability (9/20)

NovaDigm Therapeutics Inc. (Grand Forks, N.D.)

NDV-3

A prophylactic vaccine

Candida and Staphylococcus aureus

Phase I data demonstrated a single dose was safe, well tolerated and induced strong antibody and T-cell immune responses in healthy adults (9/20)

Sangamo BioSciences Inc. (Richmond, Calif.)

SB-728

Generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T cells

HIV

Phase I data showed a statistically significant relationship between suppression of HIV viral load and calculated levels of circulating CD4-positive T cells that have undergone biallelic modification of the CCR5 gene (9/20)

Trius Therapeutics Inc. (San Diego)

Tedizolid

Antibiotic tedizolid phosphate (formerly torezolid)

Acute bacterial skin and skin structure infections

A new analysis of Phase II data showed that in 95% of patients, there was no increase in size of lesion from baseline, and all 19 patients presenting with fever at the time of screening were afebrile within 24 hours (9/20)

Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

# The date indicated refers to the BioWorld Today issue in which the news item can be found.